Separately, the FDA on Friday informally requested that Sarepta voluntarily pause shipments of another gene therapy, Elevidys, that is approved to treat a different type of muscular dystrophy and was ...

Also on Friday, the Food and Drug Administration informally requested that Sarepta voluntarily pause shipments of another gene therapy, Elevidys, which is approved to treat a different type of ...

U.S. stock futures rise as investors brace for a high-stakes week packed with Tesla and Alphabet earnings and growing anxiety ...

Sarepta's gene therapy pipeline faces renewed scrutiny after a third patient death and FDA plans for a black box warning on ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged 26.85% in Friday pre-market after a clinical trial participant died ...

One of biotech’s highest fliers, Sarepta Therapeutics, lost more than a third of its market value on Friday after executives said that one of its experimental gene-replacement therapies was linked to ...

The drastic cost-cutting move follows the deaths of two teenagers that forced the company to restrict usage of its gene therapy for Duchenne muscular dystrophy.

Investors in Sarepta Therapeutics, Inc. SRPT need to pay close attention to the stock based on moves in the options market lately. That is because the Oct 18, 2024 $80 Call had some of the highest ...

Investors need to pay close attention to Sarepta Therapeutics (SRPT) stock based on the movements in the options market lately.